Bulletin of Experimental Biology and Medicine

, Volume 117, Issue 3, pp 299–301 | Cite as

Time course of the binding of some prostanoids in the serum of mice with lewis lung carcinoma with spontaneous metastases. Effect of exogenous prostaglandins on tumor dissemination

  • L. L. Mikhailevskaya
  • V. G. Vavilova
  • L. A. Selezneva
  • A. S. Kinzirskii
Oncology

Abstract

It is shown that the ability of serum to bind some prostanoids changes depending on the stage of development of the primary tumor node. Surgical removal of the tumor modulates the binding of TxB2. When the PGE2 content increases in the organism, the PGE2 binding in the serum is stepped up, and dissemination is enhanced.

Key Words

Lewis lung carcinoma metastasis prostaglandins 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Technical Guidelines for a Study of Drugs Capable of Inhibiting Metastasis and of Raising the Efficacy of Cytostatic Treatment of Malignant Tumors [in Russian], Moscow (1992).Google Scholar
  2. 2.
    O. Yu. Polevaya, E. A. Perfil'eva, L. A. Selezneva,et al., Immunologiya,4, 76 (1988).Google Scholar
  3. 3.
    Z. P. Sof'ina,Advances in Science and Technology, Ser. Oncology [in Russian], Moscow, Vol. 16, pp. 64–105.Google Scholar
  4. 4.
    C. Chiabrando, M. Broggini, M. N. Castagnoli,et al., Cancer Res.,45, 3605–3608 (1985).PubMedGoogle Scholar
  5. 5.
    P. Frost and I. J. Fidler,Cancer,58, № 2, Suppl. 2, 550–553 (1986).PubMedCrossRefGoogle Scholar
  6. 6.
    A. M. Fulton,Prostaglandins, Leukotrienes, and Essential Fatty Acids,34, 229–237 (1988).PubMedGoogle Scholar
  7. 7.
    M. R. Young and S. Knies,J. Nat. Cancer Inst.,72, 919 (1984).PubMedGoogle Scholar
  8. 8.
    M. R. Young, M. Newby, and J. Meunier,Cancer Res.,45, 3918–3923 (1985).PubMedGoogle Scholar
  9. 9.
    M. R. Young, M. E. Young, and H. T. Wepsic,,47a, 3679–3683 (1987).Google Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • L. L. Mikhailevskaya
    • 1
    • 2
  • V. G. Vavilova
    • 1
    • 2
  • L. A. Selezneva
    • 1
    • 2
  • A. S. Kinzirskii
    • 1
    • 2
  1. 1.All-Russia Center for the Safety of Biologically Active CompoundsMoscow Region
  2. 2.Industrial Center for Medical BiotechnologyMoscow

Personalised recommendations